RT Journal Article
SR Electronic
T1 Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020–March 2022, Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.11.22277481
DO 10.1101/2022.07.11.22277481
A1 Yamayoshi, Seiya
A1 Iwatsuki-Horimoto, Kiyoko
A1 Okuda, Moe
A1 Ujie, Michiko
A1 Yasuhara, Atsuhiro
A1 Murakami, Jurika
A1 Duong, Calvin
A1 Hamabata, Taiki
A1 Ito, Mutsumi
A1 Chiba, Shiho
A1 Kobayashi, Ryo
A1 Takahashi, Satoshi
A1 Mitamura, Keiko
A1 Hagihara, Masao
A1 Shibata, Akimichi
A1 Uwamino, Yoshifumi
A1 Hasegawa, Naoki
A1 Ebina, Toshiaki
A1 Izumi, Akihiko
A1 Kato, Hideaki
A1 Nakajima, Hideaki
A1 Sugaya, Norio
A1 Seki, Yuki
A1 Iqbal, Asef
A1 Kamimaki, Isamu
A1 Yamazaki, Masahiko
A1 Kawaoka, Yoshihiro
A1 Furuse, Yuki
YR 2022
UL http://medrxiv.org/content/early/2022/07/12/2022.07.11.22277481.abstract
AB Japan has reported a small number of COVID-19 cases relative to other countries. Because not all infected people receive diagnostic tests for COVID-19, the reported number of COVID-19 cases must be lower than the actual number of infections. Assessments of the presence of antibodies against the spike protein of SARS-CoV-2 can retrospectively determine the history of natural infection and vaccination. In this study, we assessed SARS-CoV-2 seroprevalence by analyzing over 60,000 samples collected in Japan from February 2020 to March 2022. The results showed that about 5% of the Japanese population had been infected with the virus by January 2021. The seroprevalence increased with the administration of vaccinations to adults; however, among the elderly, it was not as high as the vaccination rate, probably due to poor immune responses to the vaccines and waning immunity. The infection was spread during the epidemic waves caused by the SARS-CoV-2 Delta and Omicron variants among children who were not eligible for vaccination. Nevertheless, their seroprevalence was as low as 10% as of March 2022. Our study underscores the low incidence of SARS-CoV-2 infection in Japan and the effects of vaccination on immunity at the population level.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Research Program on Emerging and Re-emerging Infectious Diseases (JP19fk0108166 and 20fk0108451s0301) and Japan Program for Infectious Diseases Research and Infrastructure (JP22wm0125002) from the Japan Agency for Medical Research and Development.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the institutional review board of the Institute of Medical Science, University of Tokyo (protocol number 2019-75). The protocol was also checked and approved by each research institute and healthcare facility involved. The study participants gave informed consent during their healthcare facility visits for their data and residual samples to be used anonymously for clinical research.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.